Kathleen Irwin

Cells cultured by Hope Bio through our proprietary technology are going to work in ataxia! Houston-area clinical research organization Hope Biosciences Research Foundation (HBRF) has received Food and Drug Administration (FDA) Authorization to administer 2.4 billion HB-adMSCs to a patient with ataxia, the first FDA authorization for work in this cell type in this condition. Ataxia is a rare neurodegenerative disease that damages the cerebellum and impairs movement coordination, among other symptoms. Ataxia afflicts sufferers of any age, varies in rate of progression, and can cause life-threatening complications and early death. Read more >>> https://lnkd.in/d5juGijS

3

#ICYMI We recently announced the publication of six groundbreaking research posters at the San Antonio Breast Cancer Symposium (SABCS), showcasing our commitment to delivering on our vision to redefine precision medicine and revolutionize patient care. Our team's innovative work supports personalized treatment plans tailored to individual patient needs.    Notably, our Spatial PK/PD model stole the spotlight at SABCS, demonstrating its efficacy in predicting individual tumor response to T-DM1. Additionally, we were able to highlight a successful approach towards predicting post Neoadjuvant therapy tumor volume, surgical excision volume as well as spatial characteristics. By surpassing traditional prognostic methods, our model promises improved outcomes and enhanced quality of life for patients with breast cancer.    These findings represent a significant step forward in the fight against breast cancer and other solid tumors. Learn more about our groundbreaking research here:  https://lnkd.in/gekscjpY

36

Before your Phase II #SBIR #STTR ends, consider applying to the Phase IIB Bridge Award. This opportunity can help you past the funding gap standing between your cancer technology and subsequent financing needed to advance toward commercialization. Learn more: https://lnkd.in/em6gfqUe

2

Many innovative ideas can become obscured when communicated, which was a significant challenge for Patient Blood Management #PBM as it was introduced to benefit those suffering from #anemia, in hopes of enabling surgery without the use of donated blood upon leaving the ER (Emergency Room). The PBM educational approach supports bloodless surgical procedures. To reduce this obscurity, we are simplifying the message and increasing awareness, benefiting #researchers, manufacturers, and healthcare practitioners. Most importantly, we are enhancing the patient experience and raising public awareness. We are confident that many global organizations, healthcare providers, and blood management surgical equipment manufacturers will support our efforts as we continue to be pioneers in building a bridge of engagement for public access, which will benefit this field of medicine. Remember our medical icons, just in case one day you need direction to the OR. #Bloodlines #BBTS #Blood #SABM

6

Our IAQ Weekly Digest is here! May is National #Asthma Awareness Month, as defined by the Asthma and Allergy Foundation of America (#AAFA) since 1984. So in this edition of #IAQ in the News, we will first look at a recent #study by Stanford University showing the dangers of high levels of #nitrogen #dioxide being produced when cooking with gas stoves. Watch out for these #fumes passing through your #apartment. Next, we look at #IoT sensors being used not just to check for vaping, but also – incredibly - to #monitor general indoor air quality. Finally, it’s all kicking off in the legislature in New Brunswick, Canada. Why? Find answers from our Weekly Digest: https://lnkd.in/gRS9-8Mz

5

Today is World Asthma Day! 🫁🌎 Allergy & Asthma Network is here to support the 25+ million Americans living with #asthma. Allergy & Asthma Network continues to strive to be a trustworthy and reliable source for asthma information. Learn how we are joining Global Initiative for Asthma (GINA) 2024 theme of, "Asthma Education Empowers" in showing how asthma education empowers people to: - follow through on their treatment plan; - correctly use asthma inhalers so they get the most out of their medication; - keep symptoms well-managed; - seek an asthma specialist if symptoms worsen. Asthma education is also important for healthcare professionals. Healthcare professionals need to stay up to date on the latest asthma care guidelines. With that knowledge they can improve care for people with asthma. Learn the 6 different education programs in which Allergy & Asthma Network empowers people with asthma education: https://lnkd.in/egnCDQ53 Special thanks to Amgen , Sanofi , and Regeneron for supporting our awareness day efforts. #AsthmaAwarenessMonth #WorldAsthmaDay

69

1 Comment

It’s officially Men’s Health Month and the start to #ASCRS24. Colorectal cancer is third most common cancer among men and women in the U.S.* Come visit us at booth #420 to learn more about the utility of the 1788 Platform, SPY-PHI and Illuminated Instruments in colorectal surgery. #MensHealthMonth #ColorectalCancer #ColorectalSurgery #1788Platform *Colorectal cancer statistics: How common is colorectal cancer?. Colorectal Cancer Statistics | How Common Is Colorectal Cancer? | American Cancer Society. (n.d.). https://lnkd.in/gRvPJzKt

262

Did you know that Technology in Cancer Research & Treatment is an Open Access journal that offers tiered APC pricing for different article types? Brief Report- 20% discount Research Note- 20% discount Technical Note 20% discount Mini Review- 30% discount Commentary- 30% discount No APC for Editorials and Letters to the Editor Read more here about the journal’s article types and about other types of APC discounts 👇 https://lnkd.in/gYtrXN5v #openaccess OncoDaily #medphys #radonc #artificialintelligence #medicalimaging #immunotherapy #radiotherapy #biomarker #radiosurgery #cancerresearch

2

Every day, laboratorians nationwide provide essential health information to patients and providers. This #LabWeek, we recognize their important role in informing evidence-based health care decisions. #IamASCLS #Lab4Life #Labvocate #MLPW2024 #LabWeek #Lab4Life #TheLabIsEverything #Thankyou

2

This article discusses the current landscape of CAR T therapies and highlights the potential of a novel BCMA-targeted #oncology treatment. #celltherapy #EPRTalks

2

🗣️ “We need to determine how to preserve the effectiveness of current and future #antibiotics as long as possible – this is where in vitro diagnostics plays a key role.” – Dr. Chuck Cooper, Executive Vice President Medical Affairs, Chief Medical Officer, bioMérieux   We are committed to developing solutions to slow the spread of Antimicrobial Resistance for improved patient outcomes. Read more key quotes and highlights from our joint conference with the Ambassade de France aux Etats-Unis in DC on May 14: “Rising to the Challenge: United Against Antimicrobial Resistance”. ⤵️ #PioneeringDiagnostics

135

Empowering Choices: Navigating the New Breast Cancer Screening Recommendations. Learn how the latest guidelines from the USPSTF encourage personalized screening decisions based on individual risk factors and preferences. Link: https://lnkd.in/gkppvEF8 #BreastCancerAwareness #USPSTF #Healthcare #biedx #blogs #free #educationforall

7

Yosemite Pathology is a proud local sponsor of Go Red for Women and the American Heart Association. This year the American Heart Association celebrates its centennial year with 100 years of impact on building longer and healthier lives. #YosemitePathology #PrecisionPathology #YPMG #Pathology #Diagnostics #ClinicalPathology #Laboratory #CDC #Cytopathology #Dermatopathology #Gastroenterology #GynecologicPathology #Hematopathology #BreastPathology #ThyroidPathology #Microbiology #MolecularBiology #Biologylab #Immunology #Microbiologist #Virology #AnatomicPathology #Anatomic #FluVaccine #GoRedForWomen #WomensHealth #AmericanHeartAssociation

23

1 Comment

This #WomensHealthMonth, consider how adding #genetictesting to routine wellness checks can help identify cancer risk early, supporting women as they prioritize their health amidst life’s daily pressures. Explore genetic testing for hereditary cancer risks today: https://invit.ae/3UTwLAq

26

#ICYMI: Last year, #TeamLantheus raised nearly $200,000 to support the Prostate Cancer Foundation’s research through our Annual Golf Tournament! We’re looking forward to another year on the green raising funds for innovative #prostatecancer research.     Hear a few words from our CEO, Brian Markison, about our 29th Annual Golf Tournament!    #FindFightFollow 

66

1 Comment

The SOCRA DFW and El Paso Chapters are still taking in the amazing topic we had last month! We echo a big thank you to Eric Pittman for presenting and closing out May with the knowledge packed topic “Knock, knock, FDA is here”! We were so happy to have you and look forward to having you again in the future! If you missed this presentation, there are many more to come! But we want to hear from our members! 🫵🏼 What topics do would you like to hear? Follow us on LinkedIn to keep up with upcoming announcements from SOCRA. Interested in speaking? Send us a message or comment below ☺️ #socrates #socra #clinicalresearch #clinicaltrials #education #speakingengagements #thankyou

6

2 Comments

The SOCRA DFW and El Paso Chapters are still taking in the amazing topic we had last month! We echo a big thank you to Eric Pittman for presenting and closing out May with the knowledge packed topic “Knock, knock, FDA is here”! We were so happy to have you and look forward to having you again in the future! If you missed this presentation, there are many more to come! But we want to hear from our members! 🫵🏼 What topics do would you like to hear? Follow us on LinkedIn to keep up with upcoming announcements from SOCRA. Interested in speaking? Send us a message or comment below ☺️ #socrates #socra #clinicalresearch #clinicaltrials #education #speakingengagements #thankyou

2

May is National #CancerResearchMonth. Thanks to groundbreaking advancements in cancer care over the past several decades due to thorough and safe research, there are an estimated 18.1 million cancer survivors in the United States. We are in awe of the many strides oncology research has made in improving patients' outcomes and lives. Did you know Florida Cancer Specialists & Research Institute has one of the largest clinical research programs in the country? At FCS, we are incredibly proud of our robust, award-winning research program, which currently supports over 300 #clinicaltrials through one of our three phase 1 (early-phase) drug development units or 32 research locations at any given time. The majority of new cancer drugs for use in the U.S. were studied in clinical trials with FCS participation, prior to approval. Since the inception of our research arm, over 11,000 patients have been enrolled in these revolutionary studies, and over 600 patients participate in clinical trials each year — providing them access to the newest, most innovative drugs and treatments. This past January, we welcomed Bradley J. Monk, MD, board-certified gynecologic oncologist, to serve as the medical director of our Late-Phase Clinical Research Program. Dr. Monk's experience and portfolio in community oncology research bring us a fresh and unique set of eyes to help build upon our platform and expand our late-phase clinical trial offerings and expertise. We look forward to continuing to grow our revolutionizing program to help contribute to #cancerresearch and provide our patients with the best treatment options. To learn more, visit https://lnkd.in/eMtYF6YR.

45

May is National #CancerResearchMonth. Thanks to groundbreaking advancements in cancer care over the past several decades due to thorough and safe research, there are an estimated 18.1 million cancer survivors in the United States. We are in awe of the many strides oncology research has made in improving patients' outcomes and lives. Did you know Florida Cancer Specialists & Research Institute has one of the largest clinical research programs in the country? At FCS, we are incredibly proud of our robust, award-winning research program, which currently supports over 300 #clinicaltrials through one of our three phase 1 (early-phase) drug development units or 32 research locations at any given time. The majority of new cancer drugs for use in the U.S. were studied in clinical trials with FCS participation, prior to approval. Since the inception of our research arm, over 11,000 patients have been enrolled in these revolutionary studies, and over 600 patients participate in clinical trials each year — providing them access to the newest, most innovative drugs and treatments. This past January, we welcomed Bradley J. Monk, MD, board-certified gynecologic oncologist, to serve as the medical director of our Late-Phase Clinical Research Program. Dr. Monk's experience and portfolio in community oncology research bring us a fresh and unique set of eyes to help build upon our platform and expand our late-phase clinical trial offerings and expertise. We look forward to continuing to grow our revolutionizing program to help contribute to #cancerresearch and provide our patients with the best treatment options. To learn more, visit https://lnkd.in/eMtYF6YR.

4